STRO — Sutro Biopharma Cashflow Statement
0.000.00%
- $92.80m
- -$224.10m
- $62.04m
Annual cashflow statement for Sutro Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -32.1 | -106 | -119 | -107 | -227 |
Depreciation | |||||
Non-Cash Items | -28.5 | 36.6 | 12.7 | 22.7 | 19.8 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -11.5 | -17.6 | 104 | -34.4 | 8.9 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -67.8 | -81.7 | 3.55 | -112 | -192 |
Capital Expenditures | -7.13 | -15.3 | -7.86 | -4.32 | -3.1 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 7.73 | -82 | -27.2 | 0.391 | 222 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0.604 | -97.3 | -35 | -3.92 | 219 |
Financing Cash Flow Items | -0.314 | 0.778 | -0.463 | 138 | -0.509 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 269 | 3.26 | 48.3 | 138 | 94.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 202 | -176 | 16.8 | 22 | 121 |